|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||1.76 - 1.98|
|52 Week Range||0.65 - 2.50|
|PE Ratio (TTM)||115.62|
|Earnings Date||Nov 14, 2017 - Nov 20, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||0.54|
CARLSBAD, Calif., Sept. 20, 2017-- International Stem Cell Corporation, a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced ...
Categories: Yahoo FinanceGet free summary analysis International Stem Cell Corp. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of International Stem Cell Corp. – Keryx Biopharmaceuticals, Inc., Opexa Therapeutics, Inc., Celgene Corporation, Anthera Pharmaceuticals, Inc., Chimerix, Inc. and Vericel Corporation (KERX-US, OPXA-US, CELG-US, ANTH-US, CMRX-US and ... Read more (Read more...)
CARLSBAD, Calif., Sept. 07, 2017-- International Stem Cell Corporation, a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, today reported ...